Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 4336 AL 4350

Intensive inpatient rehabilitation for persons with Parkinson's disease: last resort or pre-emptive strike?

Radder DLM, Nonnekes J, Bloem BR.

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):795-796. doi: 10.1136/jnnp-2017-317812. Epub 2018 Mar 13.

Initial cognitive changes in Parkinson's disease

Weintraub D, Tröster AI, Marras C, Stebbins G.

Mov Disord. 2018 Apr;33(4):511-519. doi: 10.1002/mds.27330. Epub 2018 Mar 15.

The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future

Auffret M, Drapier S, Vérin M.

Drugs R D. 2018 Jun;18(2):91-107. doi: 10.1007/s40268-018-0230-3.

Functional neurological disorders in Parkinson disease

Wissel BD, Dwivedi AK, Merola A, Chin D, Jacob C, Duker AP, Vaughan JE, Lovera L, LaFaver K, Levy A, Lang AE, Morgante F, Nirenberg MJ, Stephen C, Sharma N, Romagnolo A, Lopiano L, Balint B, Yu XX, Bhatia KP, Espay AJ.

J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):566-571. doi: 10.1136/jnnp-2017-317378. Epub 2018 Mar 16.

Current perspective of mitochondrial biology in Parkinson's disease

Ammal Kaidery N, Thomas B.

Neurochem Int. 2018 Jul;117:91-113. doi: 10.1016/j.neuint.2018.03.001. Epub 2018 Mar 14.

Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease

Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ.

Mov Disord. 2018 Jul;33(6):928-936. doi: 10.1002/mds.27338. Epub 2018 Mar 23.

Medical and surgical management of advanced Parkinson's disease

Antonini A, Moro E, Godeiro C, Reichmann H.

Mov Disord. 2018 Jul;33(6):900-908. doi: 10.1002/mds.27340. Epub 2018 Mar 23.

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee.

Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23.

Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment

Litvan I, Kieburtz K, Tröster AI, Aarsland D.

Mov Disord. 2018 Apr;33(4):520-527. doi: 10.1002/mds.27345. Epub 2018 Mar 24.

A Proposed Circuit Computation in Basal Ganglia: History-Dependent Gain

Yttri EA, Dudman JT.

Mov Disord. 2018 May;33(5):704-716. doi: 10.1002/mds.27321. Epub 2018 Mar 24.

Massive Intradural Chondroma Masquerading as Lower Body Parkinsonism

Connolly ID, Johnson E, Lummus S, Hayden Gephart M.

Cureus. 2018 Jan 22;10(1):e2099. doi: 10.7759/cureus.2099.

Astrocyte dysfunction following molybdenum-associated purine loading could initiate Parkinson's disease with dementia

Bourke CA.

NPJ Parkinsons Dis. 2018 Mar 20;4:7. doi: 10.1038/s41531-018-0045-5. eCollection 2018.

Office-Based Screening for Dementia in Parkinson Disease: The Montreal Parkinson Risk of Dementia Scale in 4 Longitudinal Cohorts

Dawson BK, Fereshtehnejad SM, Anang JBM, Nomura T, Rios-Romenets S, Nakashima K, Gagnon JF, Postuma RB.

JAMA Neurol. 2018 Jun 1;75(6):704-710. doi: 10.1001/jamaneurol.2018.0254.

Using Smartphones and Machine Learning to Quantify Parkinson Disease Severity: The Mobile Parkinson Disease Score

Zhan A, Mohan S, Tarolli C, Schneider RB, Adams JL, Sharma S, Elson MJ, Spear KL, Glidden AM, Little MA, Terzis A, Dorsey ER, Saria S.

JAMA Neurol. 2018 Jul 1;75(7):876-880. doi: 10.1001/jamaneurol.2018.0809.

Microsaccade Characteristics in Neurological and Ophthalmic Disease

Alexander RG, Macknik SL, Martinez-Conde S.

Front Neurol. 2018 Mar 13;9:144. doi: 10.3389/fneur.2018.00144. eCollection 2018.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias